Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

• Discuss new data on SGLT-2 inhibitors.
• Review updated Guideline Directed Medical Therapy in Heart Failure
• Introduce a new potential breakthrough in heart transplantation- Deceased Donor Hearts
• Describe new atherectomy modality.
• Describe new percuaneous tricuspid valve intervention.
• Review the cardiac manifestation of COVID-19 and post-infection cardiac management
• Examine the indications for icosapent ethyl use among high-risk patients with elevated triglycerides
• Improve AF patient care by illustrating impact of catheter ablation on quality of life and role of wearable devices in monitoring AF.
• Improve diagnostic skills by highlighting role of artifical intellegence in cardiac electrophysiology
• Improve patient outcomes by demostrating advances in cardiac device technology including ICDs and leadless pacemakers

Suggested Additional Reading & Joint Sponsor Statement - Note: This Accreditation Statement Supersedes All Other Statements :

Suggested additional reading:

1. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. EMPEROR Trial. Packer, et. al. N Engl J Med 2020; 383:1413-1424 DOI: 10.1056/NEJMoa2022190
2. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (DAPA HF). McMurray, et. al. N Engl J Med 2019; 381:1995-2008. DOI: 10.1056/NEJMoa1911303
3. Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor therapy with Outcome for Patients with Heart Failure. Bassi, Ziaeian, Yancy, Fonarow. JAMA Cardiol. 2020;5(8):948-951. DOI:10.1001/jamacardio.2020.0898
4. Rajpal S, Tong MS, Borchers J, et al. Cardiovascular Magnetic Resonance Findings in Competitive Athletes Recovering From COVID-19 Infection. JAMA Cardiol. Published online September 11, 2020. doi:10.1001/jamacardio.2020.4916
5. Phelan D, Kim JH, Chung EH. A Game Plan for the Resumption of Sport and Exercise After Coronavirus Disease 2019 (COVID-19) Infection. JAMA Cardiol. 2020;5(10):1085–1086. doi:10.1001/jamacardio.2020.2136
6. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802–810. doi:10.1001/jamacardio.2020.0950
7. Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. Published online July 27, 2020. doi:10.1001/jamacardio.2020.3557
8. Bhatt DL, Steg PG, Miller M, et al; REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10. PMID: 30415628.
9. Bhatt DL, Miller M, Brinton EA, et al., REDUCE-IT Investigators. REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States. Circulation. 2020 Feb 4;141(5):367-375. doi:10.1161/CIRCULATIONAHA.119.044440. Epub 2019 Nov 11. PMID: 31707829; PMCID: PMC7004453.
10. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, Noseworthy PA, Rosenberg YD, Jeffries N, Mitchell LB, et al.; CABANA Investigators. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019; 321:1261–1274. doi: 10.1001/jama.2019.0693
11. Boersma LV, Ince H, Kische S, Pokushalov E, Schmitz T, Schmidt B, Gori T, Meincke F, Protopopov AV, Betts T, et al.; following investigators and institutions participated in the EWOLUTION Study. Circ Arrhythm Electrophysiol. 2019; 12:e006841. doi: 10.1161/CIRCEP.118.006841
12. Mazzanti A, Tenuta E, Marino M, et al. Efficacy and limitations of quinidine in patients with Brugada syndrome. Circ Arrhythm Electrophysiol. 2019; 12:e007143.

Joint Providership Statement:
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Pittsburgh School of Medicine designates this enduring materials activity for a maximum of 1.0 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This educational activity is approved for 1.0 contact hours.
Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.